Soligenix, Inc. (SNGX) announced on Monday that its SGX945 or Dusquetide development program for oral lesions of Behçet's Disease has received a 'Fast Track' designation from the FDA.
In the pre-market session, SNGX is at $0.850, up 11.80 percent from the previous close of $0.90 on a volume of 705,076.
The fast-track designation will help the late-stage biopharmaceutical company to submit a new drug application for SGX945 on a rolling basis.
Fast-track designation is intended to facilitate the development and expedite the review of new drugs and biologics intended to treat a serious or life-threatening condition and to address an unmet medical need.
Soligenix said its previous studies with Dusquetide in oral mucositis have clearly validated the biological activity in aphthous ulcers induced by chemotherapy and radiation.
Dusquetide, the active ingredient in SGX945 and SGX942 is said to modulate the body's reaction to both injury and infection towards an anti-inflammatory, anti-infective, and tissue healing response.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.